JKT:KLBF
PT Kalbe Farma Tbk. · JKT · Healthcare · IDR · FY for 2025
Figures on this page computed 2026-11-07 14:00 UTC
Last close
n/aIDR
Market data
We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.
9.4xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- computed
- Computed from the filing for 2025
18.5%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
10.4%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
7.0%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
0.01Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
4.8%Dividend yield
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- computed
6 of 6 traits placed on the market's range. Nothing sits below its sector's middle.
Five bars, one line
lens 7 of 9Each against its own average
4 of 5 readExcept where said otherwise: Computed from the filing for 2025
- Sales1.36x
Its own average over 10 years, 26.00T.
- Profit1.28x
Its own average over 10 years, 2.86T.
- Free cash flow1.28x
Its own average over 10 years, 1.93T.
- Debt0.48x
Its own average over 10 years, 620.31B.
- Pricen/a
Its own average over 0 years. Market data
Debt is furthest from its own average, at 0.48 times.
The filed years, as a table
10Each line is 100 at 2016-12-31, the first year we hold.
| Filed year | Sales | Profit | Shares in issue |
|---|---|---|---|
| 2016-12-31 | 100.0 | 100.0 | 100.0 |
| 2017-12-31 | 104.2 | 104.5 | 100.0 |
| 2018-12-31 | 108.8 | 106.8 | 100.0 |
| 2019-12-31 | 116.8 | 109.0 | 100.0 |
| 2020-12-31 | 119.3 | 118.9 | 100.0 |
| 2021-12-31 | 135.5 | 138.4 | 100.0 |
| 2022-12-31 | 149.3 | 147.1 | 99.2 |
| 2023-12-31 | 157.2 | 120.3 | 98.7 |
| 2024-12-31 | 168.4 | 140.9 | 98.5 |
| 2025-12-31 | 182.3 | 159.4 | 97.1 |
How sales was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- IDR
How profit was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- IDR
How shares in issue was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- IDR
Figures behind the shape
Growth
8.8%faster is higher, placed against 4,950 companies as of 2026-11-06
Five-year revenue growth rate8.8%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- computed
Five-year EPS growth rate6.7%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- computed
One-year change in net income13.1%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- computed
Returns on capital
18.5%higher is higher, placed against 5,089 companies as of 2026-11-06
Return on invested capital18.5%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity15.7%
Net Income / Shareholders' Equity x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets11.9%
Net Income / Total Assets x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
Margins
39.8%wider is higher, placed against 3,412 companies as of 2026-11-06
Gross margin39.8%
Gross Profit / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin12.9%
Operating Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin10.4%
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin7.0%
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
Price
9.4xcheaper is higher, placed against 4,362 companies as of 2026-11-06
Price to earnings9.4x
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- computed
- Computed from the filing for 2025
Price to book1.5x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDA5.4x
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio1.0x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
Safety
0.01safer is higher, placed against 3,227 companies as of 2026-11-06
Debt to equity0.01
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio3.47
Current Assets / Current Liabilities
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coverage128.9x
Operating Income / Interest Expense
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score6.75
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
What it pays out
4.8%more, and better covered, is higher, placed against 1,091 companies as of 2026-11-06
Dividend yield4.8%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- computed
Payout ratio44.6%
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ratio1.5x
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- IDR
- computed
Share a finding
A link to the finding, not to you: it carries nothing about your account.